1. Search Result
Search Result
Results for "

PT

" in MedChemExpress (MCE) Product Catalog:

76

Inhibitors & Agonists

5

Biochemical Assay Reagents

7

Peptides

3

Inhibitory Antibodies

6

Natural
Products

12

Recombinant Proteins

4

Isotope-Labeled Compounds

3

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100035

    ROCK ERK CDK Apoptosis Cancer
    PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity .
    PT-262
  • HY-163087

    Orphan Receptor Neurological Disease Metabolic Disease
    PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice .
    PT-91
  • HY-160695

    Ligands for E3 Ligase Molecular Glues Cancer
    PT-179 is an orthogonal Thalidomide (HY-14658) derivative that targets cereblon without causing off-target degradation effects. PT-179 is able to specifically bind CRBN, form a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediate the degradation of the tagged protein. For example, PT-179 binds to the ubiquitin ligase substrate receptor cereblon by forming a complex with SD40 and efficiently degrades proteins N- or C-terminally fused to SD40 or SD36 (DC50 for eGFP: 4.5 nM and 14.3 nM). PT-179 can be used to develop compact protein degradation tagging platforms .
    PT-179
  • HY-12867
    PT-2385
    Maximum Cited Publications
    47 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Cancer
    PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM .
    PT-2385
  • HY-164782

    HDAC Metabolic Disease
    PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease .
    PT3
  • HY-153166

    PROTACs GSK-3 Neurological Disease
    PT-65 is a potent and selective GSK3 PROTAC degrader with the highest degradation capacity of GSK3α (DC50= 28.3 nM) and GSK3β (DC50= 34.2 nM) in SH-SY5Y cells. PT-65 can be used in Alzheimer's disease research .(Pink: GSK3 inhibitor (HY-15761); Black: linker; Blue: CRBN Ligand (HY-10984))
    PT-65
  • HY-109146

    PT-112

    Apoptosis DNA Alkylator/Crosslinker Cancer
    Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity .
    Imifoplatin
  • HY-161509

    mTOR Cancer
    PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC50=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the treatment of breast cancer .
    PT-88
  • HY-146166

    Parasite Reactive Oxygen Species (ROS) Infection Inflammation/Immunology
    PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity .
    PT4
  • HY-125558

    ORG-34517

    Glucocorticoid Receptor Neurological Disease
    PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .
    PT150
  • HY-18678A
    Bremelanotide Acetate
    1 Publications Verification

    PT-141 Acetate

    Melanocortin Receptor Endocrinology
    Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction .
    Bremelanotide Acetate
  • HY-P10782

    Peptide-Drug Conjugates (PDCs) Cancer
    Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
    Pt(IV)-M13
  • HY-108697
    PT2399
    5 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Cancer
    PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
    PT2399
  • HY-116259

    PPAR Metabolic Disease
    PT-S58, a GSK0660 derivative, is a PPARβ/δ full antagonist with an IC50 value of 98 nM. PT-S58 inhibits the agonist-induced transcriptional activity of PPARβ/δ in vitro .
    PT-S58
  • HY-18678
    Bremelanotide
    1 Publications Verification

    PT-141

    Melanocortin Receptor Endocrinology
    Bremelanotide (PT-141) is an analogue of α-melanocyte-stimulating hormone (α-MSH). Bremelanotide activates the mPOA and other hypothalamic and limbic regions of the brain involved in sexual behavior. Bremelanotide can be used for researching hypoactive sexual desire disorders .
    Bremelanotide
  • HY-170872

    PROTACs DNA/RNA Synthesis Cancer
    PT-129 is an RPOTAC degrader targeting the NTF2 domain (protein-RNA interaction site) of G3BP1/2, which mediates the disassembly of intracellular stress granules. PT-129 can inhibit the formation of stress granules in stressed cells and disassemble existing stress granules, and can disrupt the transmission of ATF4, thereby inhibiting the proliferation of cancer cells. Stress granules (SGs) are membrane-less cytoplasmic compartments formed under stress stimuli. SGs promote the transmission of ATF4 from fibroblasts to tumor cells through a migratory effect, mediating fibroblast-related tumor growth. And G3BP1/2 is a central protein of the SGs network, and the inhibition of G3BP1/2 may reduce the stress resistance of cancer cells in the tumor microenvironment. PT-129 is composed of a target protein ligand (red part) G3BP1/2-Targeting ligand-1 (HY-170873), an E3 ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547), and a PROTAC linker (black part) Amino-PEG3-C2-acid (HY-W040165); among them, the E3 ligase ligand + linker form a complex Thalidomide-NH-PEG3-propionic acid (HY-136166) .
    PT-129
  • HY-103239

    AMPK Cardiovascular Disease Metabolic Disease
    PT1 is an AMPKα1 activator that directly activates the inactive truncated forms of AMPKα1 monomers .
    PT1
  • HY-W127821

    Biochemical Assay Reagents Others
    Pt(II) Octaethylporphine ketone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Pt(II) Octaethylporphine ketone
  • HY-167832

    JNK SGK ROCK Neurological Disease Inflammation/Immunology Cancer
    PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity .
    PT109
  • HY-136476G

    Drug Intermediate Others
    Pt(II) protoporphyrin IX is a protoporphyrin IX. Protoporphyrin IX is a heterocyclic organic compound, which consists of four pyrrole rings, and is the final intermediate in the heme biosynthetic pathway .
    Pt(II) protoporphyrin IX
  • HY-W112941

    PT(II) Meso-Tetraphenylporphine

    Biochemical Assay Reagents Others
    Meso- tetraphenylporphyrin - pt(ii) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (meso-Tetraphenylporphinato)platinum
  • HY-10824

    PT523

    Antifolate Dihydrofolate reductase (DHFR) Cancer
    Talotrexin (PT523), an analog of Aminopterin (HY-14518), is a nonpolyglutamatable classic antifolate. Talotrexin is a RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport. Talotrexin shows antitumor activity by targeting DHFR to inhibit tumor growth .
    Talotrexin
  • HY-W543137

    G-quadruplex DNA/RNA Synthesis Mitosis Cancer
    Pt-ttpy, a metallo-organic complex and potent G-quadruplex ligand, effectively triggers substantial telomere-related DNA damage in cancer cells by inhibiting telomerase and/or telomere functions, while also causing various chromatin abnormalities during mitosis, such as chromatin bridges, ultrafine bridges (UFBs), and double-stranded breaks (DSBs).
    PT-ttpy
  • HY-125840
    Belzutifan
    5+ Cited Publications

    PT2977; MK-6482

    HIF/HIF Prolyl-Hydroxylase Cancer
    Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
    Belzutifan
  • HY-13233A
    Talabostat mesylate
    35+ Cited Publications

    Val-boroPro mesylate; PT100 mesylate

    Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat mesylate
  • HY-13233

    Val-boroPro; PT100

    Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat
  • HY-P991016

    PT-217

    CD47 Inflammation/Immunology
    HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody .
    Peluntamig
  • HY-10824A

    PT523 monoammonium

    Dihydrofolate reductase (DHFR) Antifolate Cancer
    Talotrexin monoammonium is the monoammonium salt form of Talotrexin (HY-10824). Talotrexin monoammonium is an analog of Aminopterin (HY-14518), and is a nonpolyglutamatable classic antifolate. Talotrexin monoammonium is a reduced folate carrier (RFC) specific inhibitor and selectively inhibits RFC transport. Talotrexin monoammonium shows antitumor activity by targeting DHFR to inhibit tumor growth .
    Talotrexin monoammonium
  • HY-10824B

    PT523 ammonium

    Dihydrofolate reductase (DHFR) Antifolate Cancer
    Talotrexin ammonium is a nonpolyglutamatable antifolate. Talotrexin ammonium improves antitumor activity in a broad spectrum of cancer models by targeting DHFR to inhibit tumor growth .
    Talotrexin ammonium
  • HY-162133

    STING Cancer
    MSA-2-Pt is an orally active STING agonist that has good cell membrane permeability. MSA-2-Pt can induce cell death by Pt, which may release damaged DNA to activate the cGAS-STING pathway. Besides, MSA-2-Pt can activate the STING pathway directly by MSA-2. MSA-2-Pt can be used for the research of cancer .
    MSA-2-Pt
  • HY-W778423

    Dihydroxy Oxaliplatin-PT(IV)

    Drug Intermediate Cancer
    [Pt(DACH)(OH)2(ox)] (Dihydroxy Oxaliplatin-Pt(IV)) is a Oxaliplatin (HY-17371)-based Pt(IV) scaffold. [Pt(DACH)(OH)2(ox)] reacts with N-hydroxysuccinimide (NHS) ester of Pyropheophorbide-a (HY-128973) to yield phorbiplatin. Phorbiplatin is a highly potent Pt(IV) antitumor prodrug .
    [Pt(DACH)(OH)2(ox)]
  • HY-156562

    5-PropargyltryPTamide

    Biochemical Assay Reagents Others
    5-PT is a serotonin derivative that can be functionalized with various reporter groups via click chemistry to investigate protein serotonylation. 5-PT can be used in vivo to observe endogenous protein serotonylation .
    5-PT
  • HY-173089S

    Isotope-Labeled Compounds Others
    TPSLP(pT)PP(pT)REPK-(Lys- 13C6, 15N2) TFA is the 13C- and 15N-labeled TPSLP(pT)PP(pT)REPK-(Lys) TFA.
    TPSLP(pT)PP(pT)REPK-(Lys-13C6,15N2) TFA
  • HY-Y0287AS

    Isotope-Labeled Compounds Others
    Calcium carbonate,99.8%,PT- 13C is the 13C labeled Calcium carbonate,99.95-100.05%,PT .
    Calcium carbonate,99.8%,PT-13c
  • HY-156562A

    5-PropargyltryPTamide formic

    Biochemical Assay Reagents Others
    5-PT formic is a serotonin derivative that can be functionalized with various reporter groups via click chemistry to investigate protein serotonylation. 5-PT formic can be used in vivo to observe endogenous protein serotonylation .
    5-PT formic
  • HY-108697A

    HIF/HIF Prolyl-Hydroxylase Cancer
    (Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM .
    (Rac)-PT2399
  • HY-173023

    Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-P5315

    NO Synthase Others
    eNOS pT495 decoy peptide is a specific decoy peptide to prevent T495 phosphorylation reduced eNOS uncoupling and mitochondrial redistribution. eNOS pT495 decoy peptide is used in ventilator-induced lung injury research .
    eNOS pT495 decoy peptide
  • HY-16339
    N3PT
    1 Publications Verification

    N3-pyridyl thiamine

    Transketolase Cancer
    N3PT (N3-pyridyl thiamine) is a potent and selective transketolase inhibitor. N3PT is pyrophosphorylated and then binds to transketolase with an Kd value of 22 nM (Apo-TK, transketolase lacking bound thiamine) .
    N3PT
  • HY-173088S

    Isotope-Labeled Compounds Others
    IPAK(pT)PPAPK-(Lys- 13C6, 15N2) TFA is the 13C- and 15N-labeled IPAK(pT)PPAPK-(Lys) TFA.
    IPAK(pT)PPAPK-(Lys-13C6,15N2) TFA
  • HY-162092

    NF-κB IKK Cancer
    Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .
    Multi-target Pt
  • HY-173090S

    Isotope-Labeled Compounds Others
    VAVVR(pT)PPK(pS)PSSAK-(Lys- 13C6, 15N2) TFA is the 13C- and 15N-labeled VAVVR(pT)PPK(pS)PSSAK-(Lys) TFA.
    VAVVR(pT)PPK(pS)PSSAK-(Lys-13C6,15N2) TFA
  • HY-P10034

    Pss-PT

    Endogenous Metabolite Endocrinology
    Pheromonotropin (Pseudaletia separata) (Pss-PT) is an armyworm (Pseudaletia separata) pheromone with the C-terminal pentapeptide FXPRL-amide. Pheromonotropin (Pseudaletia separata) belongs to the PK/PBAN family and stimulates sex pheromone biosynthesis in moths, mediating feeding (intestinal muscle contraction), development (embryonic diapause, pupal diapause, and pupation), and defense against natural enemy insects wait .
    Pheromonotropin (pseudaletia separata)
  • HY-W781133

    cis-[PT(NH3)2(N1-pyridine)Cl]Cl

    Others Cancer
    cDPCP (cis-[Pt(NH3)2(N1-pyridine)Cl]Cl) is a DNA crosslinking agent and also a substrate for OCT1 and OCT2. DPCP exhibits anticancer activity and can improve the survival rate of sarcoma-180 mice. cDPCP is suitable for the research of colorectal cancer and cancers with appropriate cation transporters .
    cDPCP
  • HY-137787

    Drug Intermediate Others
    Cyanosafracin B is a starting material for synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 .
    Cyanosafracin B
  • HY-169023

    Apoptosis Cancer
    Antiangiogenic agent 6 (Pt-1) can inhibit angiogenesis. Antiangiogenic agent 6 can induce necroptosis in tumor cells .
    Antiangiogenic agent 6
  • HY-RS04630

    Small Interfering RNA (siRNA) Others

    F2 Human Pre-designed siRNA Set A contains three designed siRNAs for F2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    F2 Human Pre-designed siRNA Set A
    F2 Human Pre-designed siRNA Set A
  • HY-170873

    Ligands for Target Protein for PROTAC Cancer
    G3BP1/2-Targeting ligand-1 is the ligand for G3BP1/2 that can be used as target protein ligand for synthesis of G3BP1/2 PROTAC degrader PT-129 (HY-170872) .
    G3BP1/2-Targeting ligand-1
  • HY-161934

    PARP Reactive Oxygen Species (ROS) Apoptosis Cancer
    PARP1-IN-27 (Compound 9B) is the inhibitor for PARP1 and PARP2, with IC50 of 2.53 nM and 6.45 nM in cell SUM149PT. PARP1-IN-27 inhibits the proliferation of BRCA-mutated cancer cells SUM149PT, HCC1937 and Capan-1, with IC50 of 0.62, 1.91 and 4.26 μM respectively. PARP1-IN-27 aggravates DNA double-strand breaks, increases ROS generation, arrests cell cycle at G2/M phase, and induces apoptosis in SUM149PT .
    PARP1-IN-27
  • HY-P9995

    JNJ-63733657

    Tau Protein Neurological Disease
    Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
    Posdinemab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: